The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

礼来的糖尿病药物Mounjaro的销售额为38.4亿美元，超过分析师预期的38亿美元。礼来将其全年调整后每股盈利预期下调至20.78至22.28美元，低于之前的22.50至24.00美元，原因是交易费用的影响。

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

Zepbound and Wegovy were compared in a head-to-head trial to show which weight loss drug was more effective for patients.

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.